FGFR1 and bladder transitional cell carcinoma: This finding significantly expands the functional spectrum of FGFR1, as existing literature primarily documents the role of the cGMP-PKG pathway in prostate cancer, ovarian cancer, and other malignancies (48, 49), while its regulatory mechanisms in BLCA remain an emerging field of research.